Antengene Corporation Limited

DB:722 Stock Report

Market Cap: €52.8m

Antengene Past Earnings Performance

Past criteria checks 0/6

Antengene has been growing earnings at an average annual rate of 23%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 30.1% per year.

Key information

23.0%

Earnings growth rate

39.5%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate30.1%
Return on equity-53.3%
Net Margin-944.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Antengene makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:722 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2456-530283310
31 Mar 2462-555312358
31 Dec 2367-581341406
30 Sep 23123-628429470
30 Jun 23178-676518535
31 Mar 23169-639520512
31 Dec 22160-601522488
30 Sep 22121-584429469
30 Jun 2283-567335449
31 Mar 2256-611286427
31 Dec 2129-656237405
30 Sep 2114-1,640201359
30 Jun 21-2-2,624165313
31 Mar 21-1-2,777160330
31 Dec 200-2,929155348
30 Sep 204-1,842124307
30 Jun 208-75593267
31 Mar 2010-53966191
31 Dec 1911-32439116
31 Dec 187-14625116

Quality Earnings: 722 is currently unprofitable.

Growing Profit Margin: 722 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 722 is unprofitable, but has reduced losses over the past 5 years at a rate of 23% per year.

Accelerating Growth: Unable to compare 722's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 722 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).

Return on Equity

High ROE: 722 has a negative Return on Equity (-53.29%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Antengene Corporation Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyu HeChina International Capital Corporation Limited
Wangbin ZhouCitigroup Inc
Ruili BianCitigroup Inc